Details of the Drug Combination

General Information of Drug Combination (ID: DCOT1P1)

Drug Combination Name
Budesonide Methylprednisolone
Indication
Disease Entry Status REF
Chronic Obstructive Pulmonary Disease Phase 4 [1]
Component Drugs Budesonide   DMJIBAW Methylprednisolone   DM4BDON
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Budesonide
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [2]
Asthma CA23 Approved [3]
Crohn disease DD70 Approved [2]
Inflammatory bowel disease DD72 Approved [2]
Radiation proctitis N.A. Approved [2]
Ulcerative colitis DD71 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Budesonide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Antagonist [10]
------------------------------------------------------------------------------------
Budesonide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [11]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Budesonide Interacts with 28 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [13]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Expression [14]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Expression [14]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases Expression [15]
Cytosolic phospholipase A2 (PLA2G4A) OTE70SOT PA24A_HUMAN Decreases Activity [16]
Organic solute transporter subunit alpha (SLC51A) OTDJRZ0P OSTA_HUMAN Increases Expression [13]
Organic solute transporter subunit beta (SLC51B) OT4WYPSR OSTB_HUMAN Increases Expression [13]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [17]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [18]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [19]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Secretion [20]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Secretion [20]
Lactotransferrin (LTF) OT8JWCZ0 TRFL_HUMAN Decreases Secretion [21]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [22]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Secretion [23]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Expression [24]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [25]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [26]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [9]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [24]
Eosinophil cationic protein (RNASE3) OTVE2XD1 ECP_HUMAN Decreases Expression [27]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [9]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [9]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Decreases Expression [28]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Activity [29]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [30]
C-C motif chemokine 17 (CCL17) OTIKW21L CCL17_HUMAN Decreases Expression [28]
T-box transcription factor TBX21 (TBX21) OT3UK5KE TBX21_HUMAN Increases Response [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DOT(s)
Indication(s) of Methylprednisolone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [5]
Acute asthma CA23 Approved [5]
Addison disease 5A74.0 Approved [5]
Allergic rhinitis CA08.0 Approved [5]
Angioedema 4A00.15 Approved [5]
Aspiration pneumonitis N.A. Approved [5]
Autoimmune haemolytic anaemia 3A20 Approved [5]
Bursitis N.A. Approved [5]
Cerebral edema 8D60.1 Approved [5]
Chronic graft versus host disease N.A. Approved [5]
Congenital adrenal hyperplasia 5A71.01 Approved [5]
Crohn disease DD70 Approved [5]
Dermatitis herpetiformis EB44 Approved [5]
Diamond-Blackfan anemia N.A. Approved [5]
Disorder of orbital region N.A. Approved [5]
Epicondylitis N.A. Approved [5]
Erythema multiforme N.A. Approved [5]
Exanthem N.A. Approved [5]
Fever MG26 Approved [5]
Granuloma annulare N.A. Approved [5]
Inflammatory bowel disease DD72 Approved [5]
Ischemia-reperfusion injury DB98.B Approved [5]
Leukemia N.A. Approved [5]
Lupus nephritis 4A40.0Y Approved [5]
Microscopic polyangiitis N.A. Approved [5]
Miliary tuberculosis N.A. Approved [5]
Multiple sclerosis 8A40 Approved [5]
Mycosis fungoides 2B01 Approved [5]
Myeloproliferative neoplasm 2A20 Approved [5]
Pneumocystis pneumonia CA40.20 Approved [5]
Primary cutaneous T-cell lymphoma N.A. Approved [5]
Psoriasis EA90 Approved [5]
Psoriatic arthritis FA21 Approved [5]
Rheumatic heart disease N.A. Approved [5]
Rheumatoid arthritis FA20 Approved [6]
Sarcoidosis 4B20.5 Approved [5]
Seasonal allergic rhinitis CA08.01 Approved [5]
Serum sickness N.A. Approved [5]
Severe asthma CA23 Approved [5]
Skin disease EA00-EM0Z Approved [5]
Solid tumour/cancer 2A00-2F9Z Approved [6]
Systemic lupus erythematosus 4A40.0 Approved [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [7]
Acquired thrombocytopenia N.A. Investigative [5]
Asthma CA23 Investigative [5]
Beta-thalassemia major N.A. Investigative [5]
Classic Hodgkin lymphoma N.A. Investigative [5]
Follicular lymphoma 2A80 Investigative [5]
Perennial allergic rhinitis CA08.03 Investigative [5]
Spinal cord injury ND51.2 Investigative [8]
Synovitis N.A. Investigative [5]
Trichinellosis N.A. Investigative [5]
Methylprednisolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [34]
------------------------------------------------------------------------------------
Methylprednisolone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [35]
------------------------------------------------------------------------------------
Methylprednisolone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [36]
------------------------------------------------------------------------------------
Methylprednisolone Interacts with 87 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [37]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [38]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [32]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [32]
Phospholipid phosphatase 3 (PLPP3) OTSSF7BK PLPP3_HUMAN Decreases Expression [32]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) OTPGHZB9 IFIT3_HUMAN Decreases Expression [32]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [32]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Decreases Expression [32]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Decreases Expression [32]
Gasdermin-E (GSDME) OT1ZWY32 GSDME_HUMAN Decreases Expression [32]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Decreases Expression [32]
CCN family member 5 (CCN5) OTADU8JJ CCN5_HUMAN Increases Expression [32]
Antiviral innate immune response receptor RIG-I (RIGI) OTFIIC43 RIGI_HUMAN Decreases Expression [32]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Decreases Expression [32]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [32]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [32]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Decreases Expression [32]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [32]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [32]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Expression [32]
Steryl-sulfatase (STS) OTXTJQPC STS_HUMAN Increases Expression [32]
Neuromedin-B (NMB) OT4NLN6H NMB_HUMAN Decreases Expression [32]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [32]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [32]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [32]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Decreases Expression [32]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [32]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [32]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Decreases Expression [32]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Decreases Expression [32]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Decreases Expression [32]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [32]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Expression [32]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Decreases Expression [32]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Decreases Expression [32]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [32]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Decreases Expression [32]
Guanylate-binding protein 1 (GBP1) OTUM7RPJ GBP1_HUMAN Decreases Expression [32]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [32]
Macrophage metalloelastase (MMP12) OT9Z7LHM MMP12_HUMAN Decreases Expression [32]
Interferon alpha-inducible protein 27, mitochondrial (IFI27) OTI2XGIT IFI27_HUMAN Decreases Expression [32]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Decreases Expression [32]
Regulator of G-protein signaling 4 (RGS4) OTG94HHL RGS4_HUMAN Decreases Expression [32]
Prolargin (PRELP) OT9EEBUJ PRELP_HUMAN Increases Expression [32]
Spermine synthase (SMS) OT8JYKNH SPSY_HUMAN Decreases Expression [32]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Expression [32]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Decreases Expression [32]
Interferon-induced 35 kDa protein (IFI35) OTV9RZ53 IN35_HUMAN Decreases Expression [32]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [32]
Tumor necrosis factor alpha-induced protein 2 (TNFAIP2) OTRZH80H TNAP2_HUMAN Decreases Expression [32]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Increases Expression [32]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Decreases Expression [32]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Increases Expression [32]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Increases Expression [32]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Decreases Expression [32]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Increases Expression [32]
Signal transducer and activator of transcription 4 (STAT4) OTAK3VFR STAT4_HUMAN Decreases Expression [32]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Decreases Expression [32]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [32]
Lymphocyte antigen 6E (LY6E) OTMG16BZ LY6E_HUMAN Decreases Expression [32]
Interferon-induced protein 44-like (IFI44L) OTXKORJP IF44L_HUMAN Decreases Expression [32]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [32]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Decreases Expression [32]
Probable E3 ubiquitin-protein ligase HERC6 (HERC6) OT7G9PQE HERC6_HUMAN Decreases Expression [32]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [32]
Interferon-induced protein 44 (IFI44) OTOKSZVA IFI44_HUMAN Decreases Expression [32]
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2) OTCA9WCM RSAD2_HUMAN Decreases Expression [32]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Decreases Expression [32]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Increases Expression [32]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Decreases Expression [32]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Decreases Expression [32]
Interferon-induced helicase C domain-containing protein 1 (IFIH1) OTZA2AHA IFIH1_HUMAN Decreases Expression [32]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Increases Expression [32]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Decreases Expression [32]
NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2) OTK0PG7R NUA4L_HUMAN Decreases Expression [32]
E3 ISG15--protein ligase HERC5 (HERC5) OTZ5PR39 HERC5_HUMAN Decreases Expression [32]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [32]
Hypoxia-inducible lipid droplet-associated protein (HILPDA) OTEID3ZM HLPDA_HUMAN Decreases Expression [32]
2'-5'-oligoadenylate synthase 3 (OAS3) OT6E5FYS OAS3_HUMAN Decreases Expression [32]
Coagulation factor VIII (F8) OTH6XHDU FA8_HUMAN Increases Expression [33]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Decreases Expression [39]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Decreases Expression [39]
5-hydroxytryptamine receptor 3A (HTR3A) OTAIV1AK 5HT3A_HUMAN Decreases Activity [40]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Increases ADR [41]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases ADR [41]
Thrombopoietin (THPO) OTO73DZ2 TPO_HUMAN Increases ADR [41]
P-selectin (SELP) OTWR90PK LYAM3_HUMAN Increases ADR [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 87 DOT(s)

References

1 ClinicalTrials.gov (NCT01865500) Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations
2 Budesonide FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7434).
4 Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
5 Methylprednisolone FDA Label
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 ClinicalTrials.gov (NCT04341038) Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088).
9 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
10 PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
11 No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
12 Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5.
13 Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
14 Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem Pharmacol. 1998 Dec 15;56(12):1561-9.
15 Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
16 Comparison of in vitro-activity of commonly used topical glucocorticoids on cytokine- and phospholipase inhibition. Eur J Med Res. 2004 Aug 31;9(8):383-90.
17 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
18 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
19 Novel sulfhydryl-reactive compounds orazipone and OR-1958 inhibit cytokine production and histamine release in rat and human mast cells. Int Immunopharmacol. 2005 Jan;5(1):177-84. doi: 10.1016/j.intimp.2004.07.020.
20 Evaluation of the inhibitory effects of budesonide on the mitogen-induced or the allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. Ann Allergy Asthma Immunol. 1995 Jul;75(1):33-40.
21 Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: comparison between human upper and lower airways. J Allergy Clin Immunol. 2000 Dec;106(6):1053-62. doi: 10.1067/mai.2000.110476.
22 The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. Neth J Med. 1997 Jun;50(6):233-7. doi: 10.1016/s0300-2977(96)00081-2.
23 Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. Respir Med. 2000 May;94(5):428-31. doi: 10.1053/rmed.1999.0756.
24 A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 1;10(19):6502-11. doi: 10.1158/1078-0432.CCR-04-0686.
25 Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. doi: 10.1016/j.taap.2012.03.008. Epub 2012 Mar 23.
26 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
27 Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology. 2004 Nov;9(4):514-20. doi: 10.1111/j.1440-1843.2004.00631.x.
28 Effect of inhaled corticosteroid on an immunoreactive thymus and activation-regulated chemokine expression in the bronchial biopsies from asthmatics. Allergy. 2005 Mar;60(3):317-22. doi: 10.1111/j.1398-9995.2005.00694.x.
29 [Effects of beclomethasone dipropionate and budesonide on interleukin-13 induced cytokine release, proliferation and differentiation of the human lung fibroblasts]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Aug;30(8):599-604.
30 Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1939-47. doi: 10.1164/ajrccm.164.10.2103013.
31 TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18099-104. doi: 10.1073/pnas.0408532102. Epub 2004 Dec 16.
32 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
33 von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts. Pediatr Blood Cancer. 2010 Jul 1;54(7):963-9. doi: 10.1002/pbc.22466.
34 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
35 Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
36 Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
37 Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8.
38 Protective effect of methylprednisolone on paraquat-induced A549 cell cytotoxicity via induction of efflux transporter, P-glycoprotein expression. Toxicol Lett. 2012 Jan 25;208(2):101-7. doi: 10.1016/j.toxlet.2011.10.019. Epub 2011 Oct 31.
39 A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008 May;215(1):55-9. doi: 10.1620/tjem.215.55.
40 Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology. 2004 Sep;101(3):660-5. doi: 10.1097/00000542-200409000-00014.
41 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.